By the numbers: A look at the Part B International Pricing Index Model

Mounting research continues to point to how international reference pricing schemes, like the Department of Health and Human Services ’ (HHS) International Pricing Index (IPI) Model, could result in serious, unintended consequences not only for patients but for the U.S. health care system as a whole. This week, we are spotlighting recent data on the impact the proposed demonstration could have on patient access to needed treatme nts, research and development (R&D) of innovative medicines and patients ’ out-of-pocket costs. Here’s a closer look:
Source: The Catalyst - Category: Pharmaceuticals Tags: Medicare Part B Prescription for Medicare Source Type: news